The Ovary as a Target Organ for Bisphenol A Toxicity by Ptak, Anna et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
The Ovary as a Target Organ for Bisphenol A Toxicity
Anna Ptak, Marta Hoffmann and Agnieszka Rak
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.68241
Abstract
The ovary is a hormone‐sensitive organ that produces steroid hormones. Recent stud‐
ies show that bisphenol A (BPA) can affect female reproduction; thus, it is important to 
identify the possible toxic effects of BPA on the ovary because this organ is indispensable 
for fertility. This chapter summarises the effects of BPA on the ovary by describing how 
they directly affect folliculogenesis, steroidogenesis and receptor signalling and how 
they indirectly affect the expression of adipokines and/or their receptors, which exert 
endocrine or autocrine functions within the ovary.
Keywords: bisphenol A, ovary, folliculogenesis, steroidogenesis, ovarian cancer, 
adipokines
1. Introduction
In the human, female germ cells develop during the first trimester of pregnancy, whereas 
primordial follicles develop between the second and third trimesters. Females are born with 
an entire lifetime supply of non‐proliferating oocytes (primordial follicles) that survive for 
∼50 years [1]. Folliculogenesis is the process by which immature primordial follicles develop 
into preovulatory follicles (Graafian follicles). More than 99% of follicles never enter the 
preovulatory stage; instead, they undergo atresia through cell apoptosis. After ovulation, 
granulosa and theca cells undergo luteinisation and develop into the corpus luteum (CL). 
Folliculogenesis and oocyte health depend on ovarian and systemic hormones.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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The cycling ovary comprises follicles and the CL. During steroidogenesis, antral follicles 
produce oestrogens [principally 17β‐oestradiol (E
2
)] from androgens [androstenedione 
(A4) and testosterone (T)], whereas the CL produces progesterone (P
4
). This balance can 
be disrupted by altering the concentrations of oestrogen, androgen and/or P
4
 or by affect‐
ing the expression of steroid hormone receptors. The ovarian steroid hormone receptors 
include those for oestrogen (ER), androgen (AR) and P
4
 (PR), as well as those for luteinis‐
ing hormone (LH) and follicle‐stimulating hormone (FSH). The endocrine system is dis‐
rupted when a hormone can no longer bind its receptor due to a disruption in hormone 
synthesis or receptor binding (Figure 1). Additionally, a disruption in folliculogenesis or 
CL formation can lead to reproductive disturbances, such as aneuploidy, anovulation, 
decreased fertility, polycystic ovary syndrome (PCOS) and premature ovarian failure 
(POF). The overall damage to the ovary and its effects on fertility depends on the type of 
follicles affected [2].
Hormonal disturbances also underlie ovarian carcinogenesis and oestrogens, androgens, P
4
, 
LH and FSH have been proposed to promote ovarian cancer development [3]. Depending 
on the cellular origin of the tumour, ovarian cancer can be classified as epithelial, stromal 
or germinal, with each tumour possessing different histopathological features and clinical 
outcomes (Figure 2). Epithelial cell tumours account for ∼80–90% of ovarian malignancies, 
whereas stromal tumours account for ∼8%. The most frequently diagnosed type of stromal 
tumour is the granulosa cell tumour (GCT).
Previous studies show correlations between women working in graphics and printing indus‐
tries and increased risk of ovarian cancer [4], as well as between women working in similar 
industries and ovarian cancer mortality [5]. The increased incidence of ovarian cancers cannot 
be explained by genetic factors. We believe that environmental factors, such as toxic chemi‐
cals, can cause ovarian cancer, but it is very difficult to prove cause and effect.
Figure 1. Ovarian steroidogenic enzymes and steroid hormone receptors are targets of endocrine disruption. Oestrogen 
receptor (ER), androgen receptor (AR) and progesterone receptor (PR), luteinising hormone receptor (LHR) and follicle‐
stimulating hormone receptor (FSHR) and dehydroepiandrosterone (DHEA).
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2. Direct actions of BPA in the ovary
BPA accumulates in reproductive organs and disrupts the endocrine system. In the general 
population, BPA has been detected in follicular fluid at concentrations of ∼1–2 ng/ml [6]. 
Several epidemiological studies identified correlations between BPA and various abnormali‐
ties in the ovary of foetuses and adults. Moreover, the effects of BPA in the ovary, which goes 
through different stages such as folliculogenesis, ovulation and luteinisation, depend on the 
time of exposure.
2.1. BPA action on the foetal and neonatal ovary
BPA affects oogenesis and follicle formation during foetal and early postnatal periods. For 
example, BPA disrupts chromosome segregation during the first meiotic division in the foetal 
rhesus monkey ovary. During follicle formation, BPA increases the number of multiple oocyte 
follicles (MOFs), which occurs when more than one oocyte is surrounded by a single layer 
of granulosa cells [7]. BPA also disrupts meiosis and oogenesis in the foetal mouse ovary, 
thereby increasing the risks of synaptic abnormalities and aneuploidy [8]. BPA also inhibits 
germ cell nest breakdown in the foetal mouse ovary by altering the expression of apoptotic 
proteins, which can lead to various fertility problems and higher percentage of dead pups [9].
Exposure of rats to BPA during the early postnatal period decreases the primordial follicle 
reserve and increases the incidence of MOFs [10, 11]. In the neonatal mouse ovary, BPA pro‐
motes the transition of primordial follicles to primary follicles and suppresses the meiotic 
maturation of oocytes due to abnormal spindle assembly during meiosis I [12]. Additionally, 
exposure of rats to BPA during gestational and neonatal periods induces the development of 
Figure 2. Different types of ovarian cancer. Stars indicate the developmental origins of the tumour.
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PCOS‐like syndrome during adulthood [13–15]. PCOS is the most common endocrinological 
pathology in women of reproductive age. It is characterised by hyperandrogenism, insulin 
resistance and chronic anovulation.
2.2. BPA action on the adult ovary
Oocyte abnormalities were noted in adult mice exposed to BPA, possibly due to changes in 
the structural integrity of microtubules that constitute meiotic spindles [16]. BPA also disrupts 
meiotic maturation, spindle organisation and chromosome alignment and increases oocyte 
degeneration in human oocytes [17].
BPA affects ovarian steroidogenesis by modulating the expression of key steroidogenic 
enzymes. For example, BPA decreases aromatase (CYP19A1) expression and E
2
 production 
in human granulosa cells [18]. In mice, BPA inhibits P
4
, testosterone (T) and E
2
 synthesis by 
decreasing the expression of steroidogenic acute regulatory protein (Star), 3β‐hydroxysteroid 
dehydrogenase (Hsd3b1) and 17α‐hydroxylase (Cyp17a1) [19]. In rats, however, BPA increases 
P
4
 and T synthesis, as well as the expression of Star, cholesterol side‐chain cleavage enzyme 
(Cyp11a1) and Cyp17a1, but decreases E
2
 synthesis and Cyp19a1 expression [20]. In pigs, BPA 
increases basal and FSH‐induced P
4
 synthesis, whereas it decreases FSH‐induced E
2
 synthesis 
[21] (Figure 3).
In vitro studies demonstrated that BPA affects fertility by disrupting E
2
 signalling, which 
is evolutionarily conserved among mammals and indispensable for fertility. E
2
 function is 
mainly mediated by the classical nuclear oestrogen receptors ERα and ERβ. BPA can bind 
both ERα and ERβ (its affinity is higher for ERβ than ERα) [22], although its binding affinity 
for both receptors is greater than 1000–10000‐fold lower than that for E
2
 [23]. Furthermore, 
BPA can also induce oestrogen‐like effects, because BPA elicits rapid responses through non‐
classical oestrogen signalling that involves the oestrogen‐related receptor γ (ERRγ), [24, 25] as 
well as membrane‐associated G protein‐coupled receptor (GPR30) [26] (Figure 3).
Therefore, we suggest that BPA seems to be uniquely estrogenic in its receptor binding and 
androgenic in its hormone profile/steroidogenesis influences.
2.3. BPA and ovarian carcinogenesis
The correlation between BPA exposure and ovarian cancer is supported by little evidence. 
BPA exposure might increase the incidence of ovarian cysts, because women with PCOS pos‐
sess higher serum BPA levels than healthy women [27]. Furthermore, women with PCOS 
have approximately twofold to threefold increased risk of endometrial and ovarian cancers 
[28, 29]. BPA might also increase the incidence of other ovarian pathologies that ultimately 
lead to cancer.
The balance between cell proliferation and apoptotic resistance is closely linked to cancer, 
and it is generally accepted as one of the major contributing factors to cancer development. 
BPA increases the proliferation of human epithelial ovarian cancer BG‐1 [30] and OVCAR‐3 
[31] cells. The mitogenic effects of BPA are mainly mediated by the upregulation of genes 
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that induce cell proliferation (i.e., cyclin D1, cyclin A, CDK4, PCNA, E2F1 and E2F3) and the 
downregulation of genes that inhibit cell proliferation (i.e., p21, Weel‐1 and GADD45α) in 
OVCAR‐3 cells [31]. These findings are intriguing because decreased p21/WAF1 expression 
in ovarian cancer patients is an indicator of poor prognosis [32]. Furthermore, downregula‐
tion or inactivation of CDK inhibitors, such as p21Waf1/Cip1, p27Kip1 and p16Ink4a, which 
renders cells susceptible to extracellular signals that control proliferation, is often observed 
in various tumours [33]. BPA‐induced cell proliferation triggers a rapid biological response 
involving the phosphorylation of extracellular signal‐regulated kinases (ERK1/2), signal 
transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) in BG‐1 and 
OVCAR‐3 cells [30, 34]. BPA also inhibits OVCAR‐3 cell apoptosis by activating ERK1/2 sig‐
nalling [35] (Figure 4).
During tumourigenesis, cells can separate from the primary tumour to invade distant organs. 
Metastatic cancer cells undergo an epithelial‐to‐mesenchymal transition (EMT), which is 
Figure 3. BPA action on ovarian steroidogenesis. Stars indicate the sites of action. Steroidogenic acute regulatory protein 
(Star), cholesterol side‐chain cleavage enzyme (Cyp11a1), 17α‐hydroxylase (Cyp17a1), 3β‐hydroxysteroid dehydrogenase 
(Hsd3b1), aromatase (CYP19a1), oestrogen receptor (ER), androgen receptor (AR) and progesterone receptor (PR), 
luteinising hormone receptor (LHR) and follicle‐stimulating hormone receptor (FSHR), dehydroepiandrosterone (DHEA) 
and membrane‐associated G protein‐coupled receptor (GPR30).
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 characterised by the upregulation of mesenchymal proteins such as N‐cadherin, downregu‐
lation of epithelial cell‐associated proteins such as E‐cadherin and overexpression of matrix 
metalloproteinases (MMPs). MMP‐2 and MMP‐9 are the key enzymes required for the ini‐
tial steps of ovarian cancer metastasis [36, 37]. In OVCAR‐3 cells, BPA upregulates MMP‐2, 
MMP‐9 and N‐cadherin expression by activating ERK1/2 and AKT signalling, which pro‐
motes cell migration [38] (Figure 4).
Vascular endothelial growth factor‐A (VEGF‐A), which is upregulated in most solid tumours, 
including ovarian cancers, correlates with tumour progression and poor prognosis [39, 40]. 
Several studies show that the serum VEGF‐A level is higher in patients with ovarian cancer 
than in healthy individuals [41–43]. In addition, the expression of VEGF‐A and its receptor 
(VEGF‐R2) is higher in cancerous ovarian tissues than in benign or normal ovarian tissue [44]. 
BPA upregulates VEGF‐A expression in reproductive organs, such as the uterus and vagina 
in the rat [45] and the ovary in the pig [46]. Moreover, BPA markedly increases VEGF‐A and 
VEGF‐R2 expression in OVCAR‐3 and SKOV‐3 cells [47], indicating a possible intensification 
of pro‐angiogenic activity in ovarian cancer cells (Figure 4).
These findings indicate that BPA promotes the progression of epithelial ovarian cancer by 
stimulating epithelial cell proliferation and migration and inhibiting apoptosis. However, 
there is no evidence to indicate that BPA affects stromal‐ and germinal‐derived ovarian 
cancers.
Figure 4. BPA action on epithelial ovarian cancer progression. Stars indicate the sites of BPA action. The arrow facing 
up indicates a stimulation, and the arrow facing down indicates an inhibition by BPA. Matrix metalloproteinase‐2 
(MMP‐2), matrix metalloproteinase‐9 (MMP‐9), vascular endothelial growth factor‐A (VEGF‐A), vascular endothelial 
growth factor receptor 2 (VEGF‐R2), extracellular signal‐regulated kinases (ERK1/2), signal transducer and activator of 
transcription 3 (STAT3) and protein kinase B (Akt).
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3. Indirect actions of BPA in the ovary through adipokines
Leptin, apelin, chemerin and adiponectin are adipokines that are mainly produced by adipose 
tissues, but also by other tissues. Adipokines and their receptors are expressed by cells of both 
the normal and cancerous ovary in humans and other mammals. They play important roles in 
metabolic processes, such as in the regulation of insulin sensitivity, food intake, adipogenesis 
and inflammation. Adipokines also regulate ovarian function, including steroidogenesis and 
oocyte maturation. They also affect ovarian cancer cell proliferation, apoptosis, tumour inva‐
sion and angiogenesis.
The first discovered adipokine is leptin, a 167‐amino acid protein encoded by the ob gene. 
The leptin receptor [LEPR, also referred to as the obesity receptor (Ob‐R)] is a single mem‐
brane‐spanning receptor with six isoforms (Ob‐Ra, b, c, d, e and f) resulting from alternative 
RNA splicing [48]. However, only full‐length Ob‐Rb can transduce signals into cells. Leptin 
regulates food intake, energy balance and body weight [49]. For example, there is a strong cor‐
relation between the serum leptin level and body fat content; the serum leptin level is higher 
in obese individuals than in those who are non‐obese [50].
Granulosa and theca cells in mammalian ovaries express both leptin and LEPR. Leptin stimu‐
lates the production of ovarian steroid hormones by affecting insulin, insulin‐like growth fac‐
tor 1 (IGF‐1) and different gonadotrophins in the cow [51–53], pig [54, 55], rodent [56, 57] and 
human [58–60]. There is a correlation between the serum leptin level and the P
4
 concentration 
during the menstrual cycle in humans, as well as between E
2
 and human chorionic gonado‐
trophin (hCG) levels throughout pregnancy [61].
Additionally, a previous study showed an association between Ob‐Rb overexpression and 
survival in 59.2% of ovarian epithelial cell cancers [62]. OVCAR‐3 cells express both long (Ob‐
Rb) and short (ObRt) leptin isoforms [63, 64], which associate with the progression of ovarian 
epithelial cell cancers. In vitro studies show that leptin promotes BG‐1 and OVCAR‐3 cell 
proliferation [34, 63] and inhibits SKOV3, MDAH2774 and OVCAR‐3 cell apoptosis [34, 62]. 
Moreover, leptin stimulates OVCAR‐3 cell migration, which is mediated via the activation of 
ERK1/2, AKT and STAT3 signalling [65]. Leptin also acts on ovarian cancer cells in endocrine 
manner because they do not produce leptin [35].
BPA can affect the expression of adipokines. BPA increases leptin mRNA expression in the 
preadipocyte 3T3‐L1 cell line [66] and LEPR mRNA and protein expression in OVCAR‐3 
cells, which creates more binding sites for leptin [34] (Figure 5). BPA and leptin also inhibit 
the apoptosis of cancerous ovarian cells, indicating that BPA can potentiate leptin action in 
OVCAR‐3 cells [35]. These results suggest that BPA increases leptin activity in cancerous 
ovarian cells.
Apelin is a bioactive peptide that was originally identified in bovine stomach extracts as the 
endogenous ligand of the orphan G protein‐coupled apelin receptor (APJ) [67]. The apelin 
level is elevated in obese and insulin‐resistant individuals and in those with high insulin lev‐
els. Apelin functions in a broad range of physiological processes, including fluid homeostasis, 
food intake, energy metabolism, cardiovascular function and angiogenesis.
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The APJ is expressed by granulosa cells, and both apelin and its receptor are expressed by 
theca cells in the bovine ovary [68]. Apelin and APJ expression in theca cells are induced by 
LH, whereas increased APJ expression in granulosa cells associates with follicular atresia [68]. 
Apelin and APJ expression in mature follicles indicate that the apelin‐APJ system is important 
for follicle selection and dominance in cows [69]. Apelin and APJ immunoexpression have 
been reported in granulosa and theca cells, as well as in oocytes in human follicles, at different 
stages of development [70]. Furthermore, apelin promotes ovarian steroid hormone secretion, 
in particular, P
4
, and cell proliferation in pigs [71] and E
2
 synthesis in humans [70], indicating 
that apelin has a direct role in folliculogenesis. A recent in vitro study showed that apelin 
stimulates rat granulosa cell proliferation; however, apelin inhibits granulosa cell apoptosis 
via PI3K/AKT signalling [72].
Figure 5. BPA action on adipokines and their receptors expression in the epithelial ovarian cancer cells. Stars indicate 
the sites of BPA action. The arrow facing up indicates a stimulation, and the arrow facing down indicates an inhibition. 
Leptin receptor (LEPR), orphan G protein‐coupled apelin receptor (APJ), chemokine‐like receptor 1 (CMKLR1), 
adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2).
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The human KGN cell line, which is derived from granulosa‐like tumours, expresses apelin 
and APJ mRNA and protein [70]. Apelin and its receptor are also expressed by cancerous 
ovarian epithelial cell lines (OVCAR‐3, SKOV‐3 and Caov‐3), the cancerous granulosa cell 
line (COV434) and the non‐cancerous ovarian epithelial cell line (HOSEpiC). Moreover, the 
basal apelin concentration in both epithelial and granulosa cancer is 0.4–0.6 ng/ml. At these 
concentrations, apelin acts as a mitogen in these cells. However, BPA increases apelin expres‐
sion and secretion only in epithelial cancer cells (Figure 5). BPA activates the peroxisome 
proliferator‐activated receptor gamma (PPARγ) and not ERα and ERβ, because the PPARγ 
antagonist (GW9662) abolished the effects of this environmental toxicant on apelin ovarian 
expression [73].
Chemerin, also referred to as RARRES2 or TIG2, is secreted as prochemerin, an inactive pre‐
cursor that is processed into biologically active chemerin [74]. Several isoforms of biologi‐
cally active chemerin with variable C‐terminal amino acids have been characterised by their 
abilities to bind and activate the chemokine‐like receptor 1 (CMKLR1). Chemerin regulates 
adipogenesis, lipolysis and glucose metabolism.
Human granulosa and theca cells express chemerin and its receptor, CMKLR1. Chemerin 
reduces IGF‐1–induced thymidine incorporation, as well as E
2
 and P
4
 synthesis, by decreasing 
the phosphorylation of the IGF‐1R beta subunit and MAPK ERK1/2 in cultured human gran‐
ulosa cells [75]. Similarly, chemerin decreases steroid hormone production and MAPK3/1 
phosphorylation, probably through CMKLR1, in cultured bovine granulosa cells. In cumu‐
lus‐oocyte complexes, chemerin blocks meiotic progression at the germinal vesicle stage and 
inhibits MAPK3/1 phosphorylation in both oocytes and cumulus cells during in vitro matura‐
tion [76]. Chemerin also induces rat granulosa cell apoptosis and suppresses basal, and FSH‐ 
and growth differentiation factor‐9‐stimulated, follicular growth in vitro [77].
Chemerin and its receptor are expressed by KGN cells, where chemerin markedly reduces 
IGF‐1–induced cell proliferation and P
4
 and E
2
 synthesis [75]. Human cancerous ovarian epi‐
thelial cell lines (OVCAR‐3 and SKOV‐3), cancerous granulosa cell lines (COV434 and KGN) 
and the non‐cancerous ovarian epithelial cell line (HOSEpiC) also express chemerin and its 
receptor. Moreover, chemerin expression decreases in BPA‐treated GCTs (unpublished data). 
However, there is no information on the roles of chemerin in the development and progres‐
sion of ovarian cancer and no data on the serum chemerin level in patients with ovarian 
cancer.
Adiponectin (APN), also referred to as ACRP30 or AdipoQ, is the most abundant secreted 
protein expressed exclusively by adipose tissue [78]. There are three major APN isoforms, 
namely, a trimeric low‐molecular‐weight (LMW) isoform, a hexameric medium‐molecular 
‐weight (MMW) isoform and a multimeric high‐molecular‐weight (HMW) isoform [79]. 
Adiponectin binds its receptors, AdipoR1 and AdipoR2.
The expression of adiponectin and its receptors has been reported in the ovary of various 
species, including the rat, chicken, pig, cow and human [78]. Except for the cow, adiponectin 
expression is absent/low in granulosa and cumulus cells of the mouse, chicken and human. 
In the bovine ovary, adiponectin expression varies in different cells during development [80]. 
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Furthermore, adiponectin receptors are expressed by oocytes and early embryos of the pig 
and mouse [81]. In vitro studies report adiponectin to decrease insulin‐induced androgen and 
P
4
 secretion in bovine theca cells. In rat, chicken and human cultured granulosa cells, how‐
ever, adiponectin increases P
4
 and/or E
2
 secretion in response to IGF‐1. Several reports in dif‐
ferent species, including humans, indicate that adiponectin can modulate not only granulosa 
cell steroidogenesis but also the expression of genes involved in ovulation. In the cow, adipo‐
nectin decreases insulin‐induced steroidogenesis and increases IGF‐1–induced proliferation 
of cultured granulosa cells. Adiponectin does not affect oocyte maturation and embryo devel‐
opment in vitro [82]; however, it stimulates oocyte meiotic maturation and embryo develop‐
ment in the pig [81].
The serum adiponectin level is markedly lower in patients with early‐stage ovarian cancer 
than in healthy women. Adiponectin possesses anti‐tumourigenic properties; it can suppress 
tumour growth and cell proliferation, arrest cell growth and induce apoptosis. AdipoR1 
promotes KGN cell survival, whereas AdipoR2 regulates steroid hormone synthesis by acti‐
vating MAPK ERK1/2 [83]. Furthermore, the AdipoR1 mRNA level was lower in Leghorn 
chicken cancerous ovaries than in normal ovaries [84], suggesting that adiponectin signalling 
restricts ovarian cancer progression by suppressing tumour cell proliferation and inducing 
cell apoptosis.
Human cancerous ovarian epithelial cell lines (OVCAR‐3, SKOV‐3 and Caov‐3), the cancerous 
granulosa cell line (COV434) and the non‐cancerous ovarian epithelial cell line (HOSEpiC) 
express AdipoR1 and AdipoR2, but not adiponectin. Moreover, the AdipoR1 mRNA level 
is markedly higher in OVCAR‐3, SKOV‐3, Caov‐3 and COV434 cells than in HOSEpiC cells, 
whereas the AdipoR2 mRNA level is similar among all tested cell lines. BPA does not affect 
AdipoR1 and AdipoR2 expression (unpublished data), although it decreases the expression 
and secretion of adiponectin in 3T3‐L1 adipocytes [85]. In cultured porcine ovarian follicles, 
however, BPA markedly increases the expression and secretion of adiponectin, as well as the 
expression of its receptors, indicating that this environmental toxicant contributes to ovarian 
dysfunction in obesity‐related disorders (unpublished data).
4. Conclusion
BPA can alter ovarian function through several mechanisms. In this chapter, we have dis‐
cussed two mechanisms by which BPA alters ovarian function. In the first mechanism, BPA 
acts directly by reducing oocyte quality after foetal and early postnatal exposure; altering 
the expression and/or activity of key steroidogenic enzymes required for steroid hormone 
synthesis; binding to steroid hormone receptors and preventing the binding of endogenous 
ligands; stimulating ovarian cancer cell proliferation and migration; and inhibiting cell apop‐
tosis. In the second mechanism, BPA acts indirectly by altering the expression of adipokines 
and adipokine receptors, which exhibit endocrine and autocrine actions in ovarian cells. 
Further studies are needed to understand the effects of BPA on the ovary and its contribution 
to ovarian dysfunction, such as decreased fertility, PCOS and carcinogenesis.
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